Document is current
Any future updates will be listed below
-
Authors
El-Sheshtawy, Asmaa M. https://orcid.org/0009-0001-3039-5416
Werida, Rehab H. https://orcid.org/0000-0002-5983-3993
Bahgat, Monir Hussein https://orcid.org/0000-0001-7023-2454
El-Etreby, Shahira https://orcid.org/0000-0002-5879-0557
El-Bassiouny, Noha A. https://orcid.org/0000-0001-9277-2910
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06030895 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacogenomic insights: IL-23R and ATG-10 polymorphisms in Sorafenib response for hepatocellular carcinoma
https://doi.org/10.1007/s10238-025-01576-4
-
Funding
Funding for this research was provided by:
Damanhour University
- License Information
-
More Information
Article History
Received: 27 November 2024
Accepted: 23 January 2025
First Online: 8 February 2025
Declarations
:
: The authors declare no conflict of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Damanhour University (Date December 2, 2022/No. 1222pp60).
: Informed consent was obtained from all individual participants included in the study.
